Rethymic
Allogenic thymocyte-depleted thymus tissue-agdc · Sumitomo Pharma America, Inc.
PRESCRIPTION ONLY (USA)Rethymic ingredients
| Active ingredient | Strength |
|---|---|
| Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc | 22000 mm/1 |
What Rethymic is used for
Rethymic is a specialist medicine. Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Rethymic
- Generic name
- Allogenic thymocyte-depleted thymus tissue-agdc
- Made by
- Sumitomo Pharma America, Inc.
- Forms
- Implant
- Given
- Intramuscular
- FDA approval
- Biologic licence (BLA) BLA125685
- On the US market since
- 2021
Official information
- Rethymic prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Allogenic thymocyte-depleted thymus tissue-agdc)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rethymic?
Rethymic (Allogenic thymocyte-depleted thymus tissue-agdc) is a specialist medicine made by Sumitomo Pharma America, Inc., approved by the US FDA.
What are the ingredients of Rethymic?
Rethymic contains Allogeneic Thymocyte-Depleted Thymus Tissue-Agdc (22000 mm/1).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA